Showing 4961-4970 of 8785 results for "".
- Connect Biopharma to Present Additional Positive Results from the Phase 1b Study of CBP-201 for Patients with Moderate-to-Severe AD at EADV Virtual Meetinghttps://practicaldermatology.com/news/connect-biopharma-to-present-additional-positive-results-from-the-phase-1b-study-of-cbp-201-for-patients-with-moderate-to-severe-ad-at-eadv-virtual-meeting/2460574/Connect Biopharma is slated to present the full results from the Phase 1b study of CPB-201, a novel IL-4R&alpha
- Coping with COVID: Most Psoriasis Patients Taking Immunosuppressants Survive COVID-19https://practicaldermatology.com/news/coping-with-covid-most-pso-patients-taking-immunosuppressants-survive-covid-19/2460573/Patients with psoriasis who are taking drugs that affect their immune system have high rates of survival from COVID-19, according to the first findings from a global registry of psoriasis and COVID-19 patients. The initial findings from the PsoProtect registry, which appear in the
- DermOQ To Buy Skin Products's ECHO2 Plus Oxygen Facial Treatment Product Linehttps://practicaldermatology.com/news/dermoq-to-buy-skin-products-incs-echo2-plus-oxygen-facial-treatment-product-line/2460569/DermOQ Inc. is purchasing Skin Products Inc.’s ECHO2 Plus and Oxyceuticals oxygen facial treatment product lines. DermOQ offers its topical oxygen products under the brand names DermOQ Oxygen Lab and
- Eczema Missing Link Found: Researchers ID Protein that Triggers AD by Bacteriahttps://practicaldermatology.com/news/eczema-missing-link-found-researchers-id-protein-that-triggers-ad-by-bacteria/2460567/Second immunoglobulin-binding protein (Sbi) is a unique trigger of eczema by Staphylococcus aureus, according to research in the Journal of Allergy and Clinical Immunology. Sbi induces rapid release of Interleukin-33, a key component of the immune response in childhood ecz
- ADCS Acquires Montgomery Dermatology; Catawba Research Enters Partnershiphttps://practicaldermatology.com/news/adcs-acquires-montgomery-dermatology-catawba-research-enters-partnership/2460565/Advanced Dermatology and Cosmetic Surgery (ADCS), the largest dermatology practice in the US, has acquired Dermatology Associates of Montgomery, a leading dermatology practice based in the Southeast. Bundy Group served as exclusive financial advisor to Dr. Steve Maddox, owner of Dermatology
- Optical Coherence Tomography Plus AI Can Quickly and Accurately Monitor Hair Regrowthhttps://practicaldermatology.com/news/optical-coherence-tomography-plus-ai-can-quickly-and-accurately-monitor-hair-regrowth/2460564/Optical coherence tomography plus artificial intelligence methods can accurately and efficiently monitor hair growth therapies, suggests a
- EB Research Partnership and EB Research Foundation Form Largest Global Organization Advancing EB Researchhttps://practicaldermatology.com/news/eb-research-partnership-and-eb-research-foundation-form-largest-global-organization-advancing-eb-research/2460559/EB Research Partnership (EBRP), based in New York, and EB Research Foundation (EBRF) of Australia are uniting to become the largest global organization focused on funding research to discover treatments and cures for Epidermolysis Bullosa (EB). As the two leading organiza
- Brickell Biotech Initiates Phase 3 Trial of Sofpironium Bromide Gel for Hyperhidrosishttps://practicaldermatology.com/news/brickell-biotech-initiates-phase-3-trial-of-sofpironium-bromide-gel-for-hyperhidrosis/2460554/Brickell Biotech, Inc. has initiated its first pivotal US Phase 3 clinical study evaluating sofpironium bromide gel, 15% as a potential treatment for primary axillary hyperhidrosis (“Cardigan I Study”). “This continues to be an exciting time for Brickell, with initiati
- With Label Extension, Simponi Aria Approved for PsA in Kids as Young as Twohttps://practicaldermatology.com/news/with-label-extension-simponi-aria-approved-for-psa-in-kids-as-young-as-two/2460549/The FDA has approved Simponi Aria (golimumab) for the treatment of active pJIA for patients two years of age and older and has extended the PsA indication for this same patient population. In Phase 3 clinical trials with pediatric patients, pharmacokinetic (PK) exposure of
- Patients with Chronic Conditions Who Experience Telehealth Rate it Higher than Those Who Have Nothttps://practicaldermatology.com/news/patients-with-chronic-conditions-who-experience-telehealth-rated-it-higher-than-those-who-have-not/2460548/People who have tried telehealth since the onset of COVID-19 have a significantly different perception of its value than those who've not yet experienced a virtual doctor appointment, and they wish to use it again in the future. That’s the finding from a survey from